UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Myeloma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833182
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
